Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer.

Liu X, Kumar M, Yang L, Molkentine DP, Valdecanas D, Yu S, Meyn RE, Heymach JV, Skinner HD.

Clin Cancer Res. 2018 Feb 1;24(3):600-607. doi: 10.1158/1078-0432.CCR-17-1573. Epub 2017 Nov 7.

2.

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV.

Clin Cancer Res. 2017 Jun 1;23(11):2713-2722. doi: 10.1158/1078-0432.CCR-16-2586. Epub 2017 May 5.

3.

Metabolic interrogation as a tool to optimize chemotherapeutic regimens.

Sandulache VC, Chen Y, Feng L, William WN, Skinner HD, Myers JN, Meyn RE, Li J, Mijiti A, Bankson JA, Fuller CD, Konopleva MY, Lai SY.

Oncotarget. 2017 Mar 14;8(11):18154-18165. doi: 10.18632/oncotarget.15186.

4.

MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Bridges KA, Chen X, Liu H, Rock C, Buchholz TA, Shumway SD, Skinner HD, Meyn RE.

Oncotarget. 2016 Nov 1;7(44):71660-71672. doi: 10.18632/oncotarget.12311.

5.

TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.

Wang L, Zhang P, Molkentine DP, Chen C, Molkentine JM, Piao H, Raju U, Zhang J, Valdecanas DR, Tailor RC, Thames HD, Buchholz TA, Chen J, Ma L, Mason KA, Ang KK, Meyn RE, Skinner HD.

Oncogene. 2017 Feb 9;36(6):820-828. doi: 10.1038/onc.2016.250. Epub 2016 Jul 18.

6.

Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.

Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV.

Clin Cancer Res. 2016 Sep 15;22(18):4643-50. doi: 10.1158/1078-0432.CCR-15-2785. Epub 2016 Apr 1.

7.

Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.

Meyn RE, Krishnan S, Skinner HD.

Clin Cancer Res. 2016 Apr 15;22(8):1834-6. doi: 10.1158/1078-0432.CCR-16-0024. Epub 2016 Feb 26.

8.

Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model.

Sandulache VC, Chen Y, Skinner HD, Lu T, Feng L, Court LE, Myers JN, Meyn RE, Fuller CD, Bankson JA, Lai SY.

Mol Cancer Ther. 2015 Dec;14(12):2901-8. doi: 10.1158/1535-7163.MCT-15-0217. Epub 2015 Sep 16.

9.

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.

Mol Cancer Ther. 2015 Feb;14(2):608-19. doi: 10.1158/1535-7163.MCT-14-0735-T. Epub 2014 Dec 10.

10.

Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.

Raju U, Molkentine DP, Valdecanas DR, Deorukhkar A, Mason KA, Buchholz TA, Meyn RE, Ang KK, Skinner H.

Cancer Med. 2015 Jan;4(1):65-74. doi: 10.1002/cam4.345. Epub 2014 Oct 30.

11.

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.

Bridges KA, Toniatti C, Buser CA, Liu H, Buchholz TA, Meyn RE.

Oncotarget. 2014 Jul 15;5(13):5076-86.

12.

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE, Welsh JW.

Mol Ther. 2014 Aug;22(8):1494-1503. doi: 10.1038/mt.2014.79. Epub 2014 May 5.

13.

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN.

Clin Cancer Res. 2012 Jan 1;18(1):290-300. doi: 10.1158/1078-0432.CCR-11-2260. Epub 2011 Nov 16.

14.

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE.

Clin Cancer Res. 2011 Sep 1;17(17):5638-48. doi: 10.1158/1078-0432.CCR-11-0650. Epub 2011 Jul 28.

15.

Linking PTEN with genomic instability and DNA repair.

Meyn RE.

Cell Cycle. 2009 Aug;8(15):2322-3. Epub 2009 Aug 1. No abstract available.

PMID:
19633408
16.

Receptor signaling as a regulatory mechanism of DNA repair.

Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK.

Radiother Oncol. 2009 Sep;92(3):316-22. doi: 10.1016/j.radonc.2009.06.031. Epub 2009 Jul 15. Review.

17.

ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress.

Howard AN, Bridges KA, Meyn RE, Chandra J.

Cancer Chemother Pharmacol. 2009 Dec;65(1):41-54. doi: 10.1007/s00280-009-1001-1. Epub 2009 Apr 29.

PMID:
19404643
18.

The role of apoptosis in radiation oncology.

Meyn RE, Milas L, Ang KK.

Int J Radiat Biol. 2009 Feb;85(2):107-15. doi: 10.1080/09553000802662595. Review.

PMID:
19280463
19.

Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.

Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE.

Clin Cancer Res. 2008 Feb 15;14(4):1266-73. doi: 10.1158/1078-0432.CCR-07-1606.

20.

Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.

Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC.

Cancer Res. 2007 Dec 15;67(24):11687-95.

21.

Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity.

Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE.

Cancer Gene Ther. 2007 Jun;14(6):543-9. Epub 2007 Apr 13.

PMID:
17431403
22.

Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione.

Voehringer DW, Meyn RE.

Drug Resist Updat. 1998;1(6):345-51.

PMID:
17092816
23.

Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.

Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE.

Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):852-9.

PMID:
17011457
24.
25.

Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression.

Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ.

J Biol Chem. 2006 Sep 1;281(35):25134-42. Epub 2006 Jun 23.

26.

Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.

Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE Jr, Rosenblum MG.

Neoplasia. 2006 Feb;8(2):125-35.

27.

MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic.

Inoue S, Shanker M, Miyahara R, Gopalan B, Patel S, Oida Y, Branch CD, Munshi A, Meyn RE, Andreeff M, Tanaka F, Mhashilkar AM, Chada S, Ramesh R.

Curr Gene Ther. 2006 Feb;6(1):73-91. Review.

PMID:
16475947
28.

mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members.

Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, Vorburger SA, Pataer A, Swisher SG, Ramesh R, Kawase K, Meyn RE, Hunt KK.

Cancer Gene Ther. 2006 May;13(5):490-502.

PMID:
16282987
29.

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.

Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE.

Clin Cancer Res. 2005 Jul 1;11(13):4912-22.

30.

Clonogenic cell survival assay.

Munshi A, Hobbs M, Meyn RE.

Methods Mol Med. 2005;110:21-8.

PMID:
15901923
31.

Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.

Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M, Meyn RE.

Mol Cancer Ther. 2004 Aug;3(8):985-92.

32.

Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells.

Nishikawa T, Munshi A, Story MD, Ismail S, Stevens C, Chada S, Meyn RE.

Oncogene. 2004 Sep 16;23(42):7125-31.

PMID:
15273727
33.
34.

GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells.

Honda T, Coppola S, Ghibelli L, Cho SH, Kagawa S, Spurgers KB, Brisbay SM, Roth JA, Meyn RE, Fang B, McDonnell TJ.

Cancer Gene Ther. 2004 Apr;11(4):249-55.

PMID:
15002033
35.

Predicting radiosensitivity using DNA end-binding complex analysis.

Ismail SM, Puppi M, Prithivirajsingh S, Munshi A, Raju U, Meyn RE, Buchholz TA, Story MD, Brock WA, Milas L, Thames HD, Stevens CW.

Clin Cancer Res. 2004 Feb 15;10(4):1226-34.

36.

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation.

Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RE.

Cancer Gene Ther. 2004 Apr;11(4):273-9.

PMID:
14765130
37.

A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.

Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ.

Oncogene. 2004 Mar 4;23(9):1712-23.

PMID:
14647426
38.

Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity.

Sah NK, Munshi A, Nishikawa T, Mukhopadhyay T, Roth JA, Meyn RE.

Mol Cancer Ther. 2003 Nov;2(11):1223-31.

39.

Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003.

Okunieff P, Meyn RE, Teicher BA, Thomas CR Jr, Gaspar LE, Raben D, Giri S, Lavey RS, Turrisi AT 3rd, Swanson GP, Smalley SR; Radiation Oncology Committee of the Southwest Oncology Group.

Am J Clin Oncol. 2003 Oct;26(5):522-9.

PMID:
14528084
40.

MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells.

Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, Saito Y, Hunt KK, Grimm EA, Roth JA, Meyn RE, Ramesh R, Chada S.

Mol Ther. 2003 Aug;8(2):207-19.

42.
43.

Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms.

Kawabe S, Nishikawa T, Munshi A, Roth JA, Chada S, Meyn RE.

Mol Ther. 2002 Nov;6(5):637-44.

44.

A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity.

Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, Fang B, Lowe SL, Norris JS, Meyn RE, McDonnell TJ.

Cancer Biol Ther. 2002 Mar-Apr;1(2):163-7.

PMID:
12170776
45.

Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.

Munshi A, McDonnell TJ, Meyn RE.

Cancer Chemother Pharmacol. 2002 Jul;50(1):46-52. Epub 2002 May 9.

PMID:
12111111
46.

Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo.

Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, Kawabe S, Branch CD, Zumstein L, Meyn RE, Roth JA, Chada S, Ramesh R.

Oncogene. 2002 Jul 4;21(29):4558-66.

47.

Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction.

Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, Meyn RE, Roth JA, Logothetis C, McDonnell TJ.

Anticancer Res. 2001 Sep-Oct;21(5):3141-6.

PMID:
11848465
48.

P53 gene replacement for cancer--interactions with DNA damaging agents.

Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J, Meyn RE.

Acta Oncol. 2001;40(6):739-44. Review.

PMID:
11765069
49.
50.

Supplemental Content

Support Center